Division of Cardiology, Department of Internal Medicine, University of Turin, Turin, Italy.
Rev Endocr Metab Disord. 2010 Mar;11(1):87-94. doi: 10.1007/s11154-010-9136-2.
Worldwide prevalence of diabetes mellitus in the adult population is increasing and when explicitly searched within specific groups of patients, as those presenting cardiovascular disease (CVD), dysglycaemia is detected in about three-quarters of the patients. Dysglycaemia alone is a major risk factor for microvascular and macrovascular complications that impair quality of life and diminish survival. The coexistence of CVD and dysglycaemia in the same individual increases its cardiovascular risk considerably. Since a significant proportion of dysglycaemic individuals develop vascular damage and the disturbed glucose metabolism remains undetected until the first cardiovascular event, there is imperative need for improved strategies for glucometabolic health assessment and management in patients with CVD. The present review has the aim to discuss the importance of glycaemic control for future cardiovascular events starting from the in-hospital setting and continuing to long-term management based on available literature and recently updated international guidelines.
全球成年人糖尿病患病率正在上升,当在心血管疾病 (CVD) 等特定患者群体中明确搜索时,约四分之三的患者存在糖代谢异常。糖代谢异常本身就是微血管和大血管并发症的主要危险因素,这些并发症会降低生活质量并缩短生存期。CVD 和糖代谢异常同时存在于同一个人身上会大大增加其心血管风险。由于相当一部分糖代谢异常的个体发生血管损伤,而且直到首次心血管事件发生之前,葡萄糖代谢紊乱仍未被发现,因此迫切需要改进评估和管理 CVD 患者糖代谢健康的策略。本综述旨在根据现有文献和最近更新的国际指南,从住院期间开始,讨论血糖控制对未来心血管事件的重要性,一直延续到长期管理。